Paul J Diaz Myriad Genetics Inc (MYGN) insider trading activity

Paul J Diaz is President and CEO of MYRIAD GENETICS INC. Currently has a direct ownership of 962,378 shares of MYGN, which is worth approximately $12.9 Million. The most recent transaction as insider was on Oct 11, 2024, when has been sold 15,000 shares (Common Stock) at a price of $22.93 per share, resulting in proceeds of $343,950. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 962K

1.53% 3M change

15.91% 12M change

Total Value Held $12.9 Million

PAUL J DIAZ Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 11 2024	SELL Open market or private sale	$343,950 $22.93 p/Share	15,000 Reduced 1.53%	962,378 Common Stock
Sep 11 2024	SELL Open market or private sale	$400,800 $26.72 p/Share	15,000 Reduced 1.51%	977,378 Common Stock
Aug 13 2024	SELL Payment of exercise price or tax liability	$2,079,345 $28.18 p/Share	73,788 Reduced 6.92%	992,378 Common Stock
May 15 2024	SELL Open market or private sale	$1,880,250 $25.07 p/Share	75,000 Reduced 6.57%	1,066,166 Common Stock
May 14 2024	SELL Open market or private sale	$2,394,950 $25.21 p/Share	95,000 Reduced 7.69%	1,141,166 Common Stock
May 13 2024	SELL Open market or private sale	$1,453,619 $25.13 p/Share	57,844 Reduced 4.47%	1,236,166 Common Stock
Mar 24 2024	SELL Payment of exercise price or tax liability	$1,019,081 $22.24 p/Share	45,822 Reduced 3.42%	1,294,010 Common Stock
Mar 22 2024	SELL Payment of exercise price or tax liability	$449,292 $22.24 p/Share	20,202 Reduced 1.49%	1,339,832 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$647,707 $21.16 p/Share	30,610 Reduced 2.2%	1,360,034 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	246,248 Added 15.04%	1,390,644 Common Stock
Aug 13 2023	SELL Payment of exercise price or tax liability	$1,328,064 $17.89 p/Share	74,235 Reduced 6.09%	1,144,396 Common Stock
Mar 24 2023	SELL Payment of exercise price or tax liability	$1,077,481 $23.72 p/Share	45,425 Reduced 3.59%	1,218,631 Common Stock
Mar 22 2023	SELL Payment of exercise price or tax liability	$459,253 $22.91 p/Share	20,046 Reduced 1.56%	1,264,056 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	197,023 Added 13.3%	1,284,102 Common Stock
Aug 13 2022	SELL Payment of exercise price or tax liability	$1,997,584 $27.61 p/Share	72,350 Reduced 6.24%	1,087,079 Common Stock
Mar 24 2022	SELL Payment of exercise price or tax liability	$1,116,207 $25.32 p/Share	44,084 Reduced 3.66%	1,159,429 Common Stock
Mar 22 2022	BUY Grant, award, or other acquisition	-	173,144 Added 12.58%	1,203,513 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	234,271 Added 18.52%	1,030,369 Common Stock
Sep 23 2021	SELL Payment of exercise price or tax liability	$1,716,796 $34.76 p/Share	49,390 Reduced 5.84%	796,098 Common Stock
Sep 23 2021	BUY Grant, award, or other acquisition	-	445,439 Added 34.51%	845,488 Common Stock
Aug 13 2021	SELL Payment of exercise price or tax liability	$1,928,708 $32.79 p/Share	58,820 Reduced 12.82%	400,049 Common Stock
Mar 24 2021	BUY Grant, award, or other acquisition	-	159,915 Added 25.84%	458,869 Common Stock

Also insider at

DVA

DAVITA INC. Healthcare

Director

PJD

Paul J Diaz

President and CEO

Salt Lake City,, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MYGN shares.

Notify only if

Value

Insider Trading

Get notified when an Myriad Genetics Inc insider buys or sells MYGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to MYRIAD GENETICS INC

Track Activities on MYGN

Account